At a glance
ClinicalIndex Comparison RecordN/ACompleted· 23 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Endocrine, Metabolic and Microbiome Influence on the Post-acute Sequelae SARS-CoV-2 (PASC)
The University of Texas Medical Branch, Galveston·observational·Posted Apr 27, 2021·Updated Oct 28, 2024
In Brief
An observational study for Covid19. Completed, enrolled 23 participants across 1 site.
Detailed Summary
The aim of this study is characterize the endocrine, metabolic and microbiomes of patients with post-acute sequelae SARS-CoV-2 infection (PASC) and patients that have recovered from COVID without lingering symptoms.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsCovid19
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
20222023202420252026
First PostedApr 2021
Enrollment StartMay 2021
Primary CompletionMay 2022
TodayJul 2026
First PostedApr 27, 2021
Enrollment StartMay 12, 2021
Primary CompletionMay 31, 2022
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 5.2 years ago